Vedesh K Babu, MD
Internal Medicine · Stockton
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 8 years
- Graduated 2018
Offices
2 locations · Community Medical Centers, Inc. · 47 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Babu’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A187696 · Current
Licensed to practise in California · since 2023 · expires 2027-09-30 · Rajiv Gandhi University of Health Sciences, Vydehi Institute of Medical Sciences and Research Centre.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Internal Medicine
Drugs they prescribed that Part D paid
$32,856
Pharmacies billed $32,856 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 94) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.
64 generic and fewer than 11 brand-name prescriptions · $32,856 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Levothyroxine | 25 | $203 | $8 |
Year by year
| 2024 | 94 | 24 | 0% (0) | None | $32,856 |
| 2023 | 224 | 42 | 0% (0) | None | $38,326 |
| 2022 | 280 | 54 | 0% (0) | 24% | $68,861 |
| 2021 | 133 | 33 | 0% (0) | None | $21,034 |
| 2020 | 24 | 14 | 0% (0) | None | $1,599 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Metformin Hcl Er | 12 | $213 | $18 |
| Atorvastatin | 19 | $202 | $11 |
| Levothyroxine | 12 | $194 | $16 |
| Amlodipine Besylate | 16 | $96 | $6 |
2022: 4 drugs
| Levothyroxine | 25 | $444 | $18 |
| Atorvastatin | 22 | $208 | $9 |
| Metformin | 16 | $93 | $6 |
| Amlodipine Besylate | 13 | $72 | $6 |
Money from drug and device companies
$558 in 2025
| 2025 | 7 | 11 | None | $558 |
| 2024 | 3 | 5 | None | $509 |
| 2023 | 4 | 4 | None | $380 |
| 2022 | 3 | 4 | None | $157 |
| 2021 | 1 | 1 | None | $114 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Corcept Therapeutics | Korlym | $200 | 2 payments
|
| Amgen | Tepezza | $141 | 2 payments
|
| Novartis Pharmaceuticals | Leqvio | $74 | 1 payment
|
| Lilly USA | Mounjaro | $49 | 2 payments
|
| Novo Nordisk | Rybelsus | $43 | 2 payments
|
| Insulet | Omnipod | $29 | 1 payment
|
See all 11 published payments
| Amgen | Meals · 2025-11-25 | Tepezza | $5 |
| Novo Nordisk | Meals · 2025-11-04 | Rybelsus | $28 |
| Lilly USA | Meals · 2025-10-21 | Mounjaro | $20 |
| Insulet | Meals · 2025-10-15 | Omnipod | $29 |
| Novo Nordisk | Meals · 2025-10-09 | Rybelsus | $14 |
| Dexcom | Meals · 2025-09-24 | Dexcom G6 Transmitter | $22 |
| Lilly USA | Meals · 2025-08-26 | Mounjaro | $29 |
| Amgen | Meals · 2025-07-13 | Tepezza | $137 |
| Corcept Therapeutics | Meals · 2025-05-07 | Korlym | $109 |
| Corcept Therapeutics | Meals · 2025-02-12 | Korlym | $91 |
| Novartis Pharmaceuticals | Meals · 2025-01-27 | Leqvio | $74 |
See earlier years (2024, 2023, 2022, 2021)
2024: $509
| Corcept Therapeutics | Korlym | $302 | 3 payments
|
| Amgen | None | $118 | 1 payment
|
| Mannkind | Afrezza | $90 | 1 payment
|
2023: $380
| Kyowa Kirin | None | $125 | 1 payment
|
| MannKind | V-Go | $122 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $96 | 1 payment
|
| Corcept Therapeutics | Korlym | $37 | 1 payment
|
2022: $157
| Genentech USA | None | $102 | 1 payment
|
| Lilly USA | Humulin | $35 | 2 payments
|
| Ultragenyx Pharmaceutical | Crysvita | $19 | 1 payment
|
2021: $114
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $114 | 1 payment
|
Professional record
- NPI
- 1487262267
- Licence
- CA 187696California A187696: Current · expires 2027-09-30
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RE0101X (207RE0101X)
- Mailing address
- 7912 West Ln Ste 221, Stockton, CA, 95210
- NPI first listed
- 2020-07-17
- NPI last updated
- 2025-07-21
- NPI record certified
- 2025-07-21
This is when the NPI record was last certified, not a medical board exam.